Psychometric evaluation of a daily gastro-oesophageal reflux disease symptom measure

Abstract

Based on existing evidence, the HRDQ is a valid and reliable measure of GORD symptoms that can be used as a study outcome in clinical trials.

Randomised clinical trial: addition of alginate‐antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms

“…Primary efficacy data were based on the HRDQ, a measure designed specifically to capture symptoms that are most relevant for patients with uncontrolled GERD symptoms while taking daily PPIs. The HRDQ was adapted from the two most extensively tested patient‐reported outcome measures, the RDQ and ReQuest questionnaires which, while well‐validated, are not designed for patients with residual GERD symptoms while on therapy.…”

“…Previous studies indicate that addition of alginate may help maintain symptom control at initiation of PPI treatment and when stepping down to a maintenance dose or discontinuing PPIs, a period when rebound acid hypersecretion can be problematic . The only published randomised clinical trial to investigate alginate (Gaviscon Advance) as add‐on therapy in patients with breakthrough symptoms demonstrated a reduction in reflux symptoms using the validated Heartburn Reflux Dyspepsia Questionnaire (HRDQ) daily recall patient questionnaire as the outcomes measure. This study reported absolute changes in HRDQ scores from baseline, with significantly greater reductions being observed for add‐on Gaviscon Advance vs placebo.…”

“…This study reported absolute changes in HRDQ scores from baseline, with significantly greater reductions being observed for add‐on Gaviscon Advance vs placebo. Since publication of the study, the HRDQ scale has been further evaluated and clinically relevant response status has been defined . An HRDQ cut‐off score of 0.70 was selected based on correlation with the established ReQuest symptom threshold of 0.95.…”

“…An HRDQ cut‐off score of 0.70 was selected based on correlation with the established ReQuest symptom threshold of 0.95. The 0.70 cut‐off for definition of a “bad day” was evaluated and response was defined as reduction of three or more days in a week with an HRDQ score >0.7 …”

Editorial: refractory GERD—good drug, wrong patients?

“…It has been successfully used first line for post-prandial heartburn, and as an add-on to PPI in refractory GERD 8 determined by HRDQ. 9 Coyle et al first reported an exploratory study that demonstrated superiority of Gaviscon DA over placebo in patients with continued frequent heartburn, an abnormal HRDQ score and compliance with once daily PPI. However, their larger, confirmatory study changed the scoring of the HRDQ for the primary outcome.…”